Bispecific Antibodies in R/R FL and R/R DLBCL

Aligning on Clinical Best Practices CME/CNE/CPE

Chicago Hilton
Sunday, June 1, 2025 | 6:45 PM - 8:15 PM TZ
event presence logo
Supported by an independent educational grant from Genmab US, Inc. and AbbVie.

overview

Join us for an enlightening 90-minute live symposium designed exclusively for hematologists and oncologists treating relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL). As the landscape evolves, staying abreast of innovative therapies is crucial for optimizing patient outcomes. This symposium offers a unique opportunity to engage with leading experts in the field, gain insights from clinical trial data, and explore practical applications of bispecific antibody therapy in your practice.

Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation.

Enhance Your Experience With MedChallenge!

This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!

faculty

Chair

Gilles Salles, MD, PhD

​Professor of Medicine

​Chief of the Lymphoma Service

​Memorial Sloan Kettering Cancer Center

Weill Cornell Medicine

​New York, New York

Panelist

​​Joshua Brody, MD

​Director, Lymphoma Immunotherapy Program

​Icahn School of Medicine at Mount Sinai

​Hess Center for Science and Medicine

​New York, New York

Panelist

​​Tycel Phillips, MD

​Associate Professor, Division of Lymphoma,

​Department of Hematology & Hematopoietic Cell Transplantation

​City of Hope

Duarte, California

AGENDA

6:15 PM TZ

Dinner and Registration

6:45 PM TZ

Welcome and Introductions

Gilles Salles, MD, PhD​

6:50 PM TZ

The FL Patient: Highlighting and Applying Clinical Trial Data in R/R FL

Joshua Brody, MD

7:15 PM TZ

The DLBCL Patient: Highlighting and Applying Clinical Trial Data in R/R DLBCL

Tycel Phillips, MD

7:40 PM TZ

Choosing the Right Bispecific Antibody Therapy and Aligning Best Practices for Use

All Faculty

8:10 PM TZ

Concluding Remarks and Audience Q&A

Gilles Salles, MD, PhD​
backstage pass
Enhance Your Virtual Experience With Backstage Pass! Backstage Pass provides an intimate virtual session where you can interact with faculty, address case-based questions, and facilitate relationship building.
*Video encouraged*

LOCATION

Chicago Hilton

720 S Michigan Ave, Chicago, IL, 60605

Room: International North

TARGET AUDIENCE

This educational activity is intended for an audience of hematologists/oncologists, physician assistants, nurse practitioners, pharmacists, and other members of the oncology care team in the United States.

GOAL STATEMENT

The goal of this activity is for learners to be better able to integrate bispecific antibodies into the management of R/R FL and R/R DLBCL by understanding the supporting clinical evidence and implementation strategies.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:
  • Identify key clinical trial data for bispecific antibodies in R/R FL and R/R DLBCL
  • Implement practical management strategies to optimize the use of bispecific antibodies in R/R FL and R/R DLBCL
  • Interpret selection criteria for bispecific antibody therapy based on current FL and DLBCL practice guidelines
  • Integrate the latest data on bispecific antibodies to individualize the care of patients with R/R FL and R/R DLBCL

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
accreditation logo
medscape logo

For Physicians

Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For Nurses

Awarded up to 1.5 contact hour(s) of nursing continuing professional development for RNs and APNs.


For Pharmacists

Medscape designates this continuing education activity for ​1.5 contact hour(s) (​0.15​ CEUs) (Universal Activity Number: ​JA0007105-0000-25-151-L01-P​).

© 2025 MedscapeLIVE! All Rights Reserved | Medscape Education Terms of Service | Privacy Policy